Literature DB >> 10102952

Glucose metabolism and insulin sensitivity in inactive inflammatory bowel disease.

E Capristo1, G Mingrone, G Addolorato, A V Greco, G Gasbarrini.   

Abstract

BACKGROUND: Inflammatory mediator concentration was found to be increased in active inflammatory bowel disease, and this could be related to an insulin-resistant state. Moreover, glucocorticoids, which are widely used in the treatment of inflammatory bowel disease, are notoriously related to insulin resistance. AIM: To measure body composition, whole body glucose uptake and oxidation in Crohn's disease and ulcerative colitis patients with inactive disease.
METHODS: All patients had clinical, ultrasound and biochemical assessment. Body composition was determined by isotopic dilution technique; basal metabolic rate and substrate oxidation were measured by indirect calorimetry. Insulin sensitivity was assessed by the euglycaemic hyperinsulinaemic clamp. Ten patients with inactive Crohn's disease (five males, aged 31.1 +/- 7.0 years) and 10 patients with inactive ulcerative colitis (five males, aged 33.4 +/- 8.8 years) participated in the study. Forty healthy subjects, matched for age and height were used as a control group.
RESULTS: Crohn's disease patients showed lower BMI (P < 0.001), fat mass (P < 0.05) and respiratory quotient (P < 0.001) values compared to both ulcerative colitis and control subjects. No difference in peripheral glucose uptake (micromol/kg/min) was found between groups (respectively 42.5 +/- 6.78 in Crohn's disease, 40.2 +/- 8.00 in ulcerative colitis and 41.4 +/- 10.8 in control subjects). Glucose storage and oxidation did not differ between groups.
CONCLUSION: Our data showed that inflammatory bowel disease patients in a remission phase of the disease activity had a whole body glucose uptake and oxidation similar to those of control subjects, probably due to fat-free mass preservation and low blood and tissue cytokine concentration.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10102952     DOI: 10.1046/j.1365-2036.1999.00461.x

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  9 in total

1.  Inhibition of LncRNA-NEAT1 alleviates intestinal epithelial cells (IECs) dysfunction in ulcerative colitis by maintaining the homeostasis of the glucose metabolism through the miR-410-3p-LDHA axis.

Authors:  Siyi Ni; Yingchao Liu; Jihong Zhong; Yan Shen
Journal:  Bioengineered       Date:  2022-04       Impact factor: 6.832

2.  Impact of lipoprotein lipase gene polymorphisms on ulcerative colitis.

Authors:  Toshihito Kosaka; Junji Yoshino; Kazuo Inui; Takao Wakabayashi; Kazumu Okushima; Takashi Kobayashi; Hironao Miyoshi; Yuta Nakamura; Shigekazu Hayashi; Taizou Shiraishi; Masatoshi Watanabe; Takayuki Yamamoto; Ai Nakahara; Takahiko Katoh
Journal:  World J Gastroenterol       Date:  2006-10-21       Impact factor: 5.742

3.  Metabolic syndrome frequency in inflammatory bowel diseases.

Authors:  Elif Yorulmaz; Gupse Adali; Hatice Yorulmaz; Celal Ulasoglu; Guralp Tasan; Ilyas Tuncer
Journal:  Saudi J Gastroenterol       Date:  2011 Nov-Dec       Impact factor: 2.485

Review 4.  Endocrine and metabolic manifestations in inflammatory bowel disease.

Authors:  Stelios Tigas; Agathocles Tsatsoulis
Journal:  Ann Gastroenterol       Date:  2012

5.  Relationship between maternal hypoglycaemia and small-for-gestational-age infants according to maternal weight status: a retrospective cohort study in two hospitals.

Authors:  Satoshi Shinohara; Yuzo Uchida; Mitsuo Hirai; Shuji Hirata; Kohta Suzuki
Journal:  BMJ Open       Date:  2016-12-02       Impact factor: 2.692

6.  Are adipocytokines inflammatory or metabolic mediators in patients with inflammatory bowel disease?

Authors:  Resul Kahraman; Turan Calhan; Abdurrahman Sahin; Kamil Ozdil; Zuhal Caliskan; Elif Sinem Bireller; Bedia Cakmakoglu
Journal:  Ther Clin Risk Manag       Date:  2017-09-30       Impact factor: 2.423

7.  Favorable Effect of Anti-TNF Therapy on Insulin Sensitivity in Nonobese, Nondiabetic Patients with Inflammatory Bowel Disease.

Authors:  Stavroula A Paschou; Fotios Kothonas; Apostolos Lafkas; Alexandros Myroforidis; Vasiliki Loi; Thomais Terzi; Olympia Karagianni; Androniki Poulou; Konstantinos Goumas; Andromachi Vryonidou
Journal:  Int J Endocrinol       Date:  2018-03-05       Impact factor: 3.257

Review 8.  Body Mass Index Is Associated with Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis.

Authors:  Jie Dong; Yi Chen; Yuchen Tang; Fei Xu; Chaohui Yu; Youming Li; Prasoon Pankaj; Ning Dai
Journal:  PLoS One       Date:  2015-12-14       Impact factor: 3.240

9.  Serum adropin levels are reduced in patients with inflammatory bowel diseases.

Authors:  Darko Brnić; Dinko Martinovic; Piero Marin Zivkovic; Daria Tokic; Ivana Tadin Hadjina; Doris Rusic; Marino Vilovic; Daniela Supe-Domic; Ante Tonkic; Josko Bozic
Journal:  Sci Rep       Date:  2020-06-09       Impact factor: 4.379

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.